Belantamab Mafodotin
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 235 publications
Comparative Efficacy of Belantamab Mafodotin in Combination With Bortezomib and Dexamethasone Versus Standards of Care in Patients With Third-Line or Later Relapsed/Refractory Multiple Myeloma.
Journal: American journal of hematology
Published: April 24, 2026
Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Patients With Relapsed/Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Renal Function.
Journal: Clinical lymphoma, myeloma & leukemia
Published: April 10, 2026
Cutaneous adverse events with antibody-drug conjugates: a FAERS-based pharmacovigilance study.
Journal: Frontiers in medicine
Published: April 03, 2026
A review of the clinical efficacy of monoclonal antibody (mAb)-based therapies for relapsed/refractory multiple myeloma (RRMM).
Journal: Expert opinion on biological therapy
Published: March 17, 2026
The Evolution of Chimeric Antigen Receptor T-Cell, Bispecific Antibodies and Antibody-Drug Conjugates for the Treatment of Multiple Myeloma.
Journal: Clinical lymphoma, myeloma & leukemia
Published: February 06, 2026
Simulation Framework to Investigate Efficacy and Ocular Safety of Belantamab Mafodotin Combinations in Relapsed/Refractory Multiple Myeloma.
Journal: CPT: pharmacometrics & systems pharmacology
Published: December 19, 2025
Addressing unmet needs in relapsed/refractory multiple myeloma: an Italian Delphi consensus on current challenges and emerging therapies.
Journal: Frontiers in oncology
Published: November 28, 2025
Salvage Therapies After Anti-BCMA CAR-T Failure in Patients With Multiple Myeloma: A Meta-Analysis of Response Rates.
Journal: European journal of haematology
Published: November 10, 2025
Belantamab mafodotin for the treatment of multiple myeloma.
Journal: Expert opinion on biological therapy
Published: October 15, 2025
Last Updated: 06/30/2026